C. Ola Landgren, Leader of Translational and Clinical Oncology Program/Experimental Therapeutics at Sylvester Comprehensive Cancer Center, shared a post on LinkedIn:
“At Sylvester Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, we are partnering with leaders across diagnostics, pharma, biotech, and health-tech to accelerate scientific innovation and deliver clinically important, real-world impact. Our Institute is helping to redefine the future of multiple myeloma care.
Empowered by state-of-the-art MRD technologies, advanced predictive AI-based modeling, and robust computational analytics, we have established ourselves as an international leader in the development and evaluation of breakthrough therapies.
Our progress is driven by deeply collaborative, multidisciplinary teams who share one mission: to transform how multiple myeloma is understood, detected, and treated around the world.
We are continuously seeking bold ideas and forward-thinking partners. If you’re interested in innovating with us, we invite you to connect—and to visit us here in beautiful Miami.
We look forward to hearing from you!”
Proceed to watch the video attached to the post.
More posts featuring C. Ola Landgren.